Mallinckrodt Hospital Products INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$34Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
37,556clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2020 $5.2M
2021 $4.8M
2022 $5.9M
2023 $4.9M
2024 $6.6M
2025 $6.3M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Ophthalmology $6.2M
Nephrology (Internal Medicine) $4.8M
Rheumatology $4.7M
Pulmonary Disease $4.0M
Gastroenterology (Internal Medicine) $3.1M
Neurology (Psychiatry & Neurology) $1.3M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Stephen Pappas Houston, TX Gastroenterology (Internal Medicine) $1,121,599.23
Kostas Botsoglou Cheektowaga, NY Rheumatology $664,044.36
Melissa Toyos Memphis, TN Ophthalmology $627,563.69
Stephen Anesi Waltham, MA Ophthalmology $616,327.11
Peter Chang Waltham, MA Ophthalmology $609,689.67
Paul Karpecki Lexington, KY Optometrist $602,690.40
John Affeldt Loma Linda, CA Ophthalmology $528,164.73
Abdul Abdellatif Webster, TX Nephrology (Internal Medicine) $520,613.20
Robert Baughman Cincinnati, OH Pulmonary Disease $518,502.94
Steven Silverstein Kansas City, MO Ophthalmology $493,843.44

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.